Rheumatoid arthritis and tumor necrosis factor α

Autoimmunity

Volumn 34, Issue 4, 2001, Pages 291-303

  Abe, Tohru ^a   Takeuchi, Tsutomu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTIRHEUMATIC AGENT; CHEMOKINE; CYTOKINE; CYTOKINE RECEPTOR; FOLIC ACID ANTAGONIST; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TYROSINE KINASE RECEPTOR;

AUTOIMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; REVIEW; RHEUMATOID ARTHRITIS; VIRUS ETIOLOGY;

EID: 0035714009     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916930109014698     Document Type: Review

References (105)

1. Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis
2. The occurrence of autoantibodies in infectious mononucleosis
3. Antineutrophil antibodies in infectious mononucleosis
4. Anti-cardiolipin antibodies in infectious mononucleosis react with the membrane of activated lymphocytes
5. Lymphocytes transformed by Epstein-Barr virus: Induction of nuclear antigen reactive with antibody in rheumatoid arthritis
6. Antibodies to the Epstein-Barr virus nuclear antigen and rheumatoid arthritis nuclear antigen identify the same polypeptide
7. The Epstein-Barr virus glycoprotein gp110, a molecular link between HLA-DR4, HLA-DR1 and rheumatoid arthritis
8. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 β 1 chain and the Epstein-Barr virus glycoprotein gp110
9. Positive selection in autoimmunity: Abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis
10. Spontaneous establishment of an Epstein-Barr virus-infected fibroblast line from the synovial tissue of a rheumatoid arthritis patient
11. Bone marrow CD34+ progenitor cells from rheumatoid arthritis patients give rise to spontaneous transformation of peripheral blood B cells from Epstein-Barr virus uninfected healthy individuals
12. Potential role of Epstein-Barr virus in Sjogren syndrome and rheumatoid arthritis
13. Human parvovirus arthropathy
14. Human parvovirus arthropathy and rheumatoid factor
15. Parvovirus B-19 and erosive polyarthritis
16. Human parvovirus infection in early rheumatoid and inflammatory arthritis
17. Persistence of B-19 parvovirus in synovial membranes of patients with rheumatoid arthritis
18. Persistent parvovirus B-19 infection
19. Persistence of parvovirus B-19 DNA in synovial membranes of young patients with and without chronic arthropathy
20. Parvovirus B-19 specific DNA in bone marrow from B-19 arthropathy patients: Evidence for B-19 virus persistence
21. HTLV-1 associated myelopathy. A new clinical entity
22. Chronic inflammatory arthropathy associated with HTLV-1
23. Arthritis in patients infected with human T lymphotropic virus type 1. Clinical and immunopathologic features
24. Absence of lentiviral and human T cell leukemia viral sequences in patients with rheumatoid arthritis
25. Polymerase chain reaction fails to incriminate exogenous retroviruses HTLV-1 and HIV-1 in rheumato-logical diseases although a minority of sera cross react with retroviral antigens
26. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-1
27. Virus-like particles in synovial fluids from patients with rheumatoid arthritis
28. Molecular and cellular mechanism of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction?
29. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy
30. Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus
31. The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
32. Positive and negative association of HLA-DR genotypes with Japanese rheumatoid arthritis
33. Rheumatoid arthritis: A disease of T-lymphocyte/macrophage immunoregulation
34. Evidence in support of a self perpetuating HLA-DR dependent delayed type cell reaction in rheumatoid arthritis
35. Synergy between T cell receptor β gene polymorphism and HLA-DR4 in susceptibility to rheumatoid arthritis
36. Analysis of a T cell receptor V β segment implicated in susceptibility to rheumatoid arthritis: V β 2 germline polymorphis does not encode susceptibility
37. The role of T cell receptor β chain gene in susceptibility to rheumatoid arthritis
38. A linkage study across the T cell receptor A and T cell receptor B loci in families with rheumatoid arthritis
39. Association of tumor necrosis factor microsatellite polymorphisms with HLA-DR β 1-0401 bearing haplotypes in rheumatoid arthritis patients
40. HSP-70-1 promoter region alleles and susceptibility to rheumatoid arthritis
41. Very late activation antigens on rhematoid synovial fluid T lymphocytes: Association with stages of T cell activation
42. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis
43. Adhesion molecule expression in human synovial tissue
44. Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis: Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes
45. Chondrocyte-derived cells and matrix at the rheumatoid cartilage-pannus junction identified with monoclonal antibodies
46. Using inhibitors of metalloproteinases to treat arthritis
47. Lysosomal cysteine endopeptidases in the degradation of cartiage and bone
48. Fas and FasL interaction is necessary for human osteoblast apoptosis
49. Interleukin 15: A proinflammatory role in rheumatoid arthritis synovitis
50. Role of cytokines in rheumatoid arthritis
51. Immuno-regulatory role of interleukin 10 (IL-10) in RA
52. Elevated IL-10 levels in patients with RA
53. Balance of IL-1 receptor antagonist/IL-1 β in rheumatoid synovium and its regulation by IL-4 and IL-10
54. IL-10 is a potent growth and differentiation factor for activated human B lymphocytes
55. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with Yersinia-induced arthritis and osteoarthritis
56. Interleukin 15 mediates T cell-dependent regulation of TNF α production in rheumatoid arthritis
57. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin 10 possible relevance to pathophysiology of rheumatoid arthritis
58. Human IL-17: A novel cytokine derived from T cells
59. T cell interleukin 17 induces stromal cells to produce proinflammatory and hematopoietic cytokines
60. Myofibroblastic stromal cells isolated from human bone marrow induce the proliferation of both early myeloid and B-lymphoid cells
61. IL-17 in synovial fluids from patients with RA is a potent stimulator of osteoclastogenesis
62. Il-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses
63. Cutting edge: Generation of IL-18 receptor-deficient mice: Evidence for IL-1 receptor-mediated protein as an essential IL-18 binding receptor
64. IL-18 upregulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor
65. IL-18 is produced by articular chondrocyte and induces proinflammatory and catabolic responses
66. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of IL-1
67. Inhibitory effect of TNF α antibodies on synovial cell interleukin 1 production in rheumatoid arthritis
68. Expression of granulocyte-macrophage colony-stimulating factor in RA: Regulation by tumor necrosis factor- α
69. Antibodies to cachectin/tumor necrosis factor reduce IL-1 β and IL-6 appearance during letheal bacteremia
70. Blockade of TNF α with chimeric anti-TNF αmonoclonal antibody, cA2 reduces IL-6 and IL-8 release in RA mononuclear cell cultures: A comparison with IL-1 ra
71. The interleukin-1 family: 10 year of discovery
72. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumor necrosis factor or transforming growth factor β
73. Effects of tumor necrosis factor α (TNF α) on collagen arthritis
74. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice
75. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
76. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
77. Transgenic and knockout analysis of the role of TNF in immune regulation and disease pathogenesis
78. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
79. Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis
80. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
81. Isolation and characterization of a tumor necrosis factor binding protein from urine
82. Soluble tumor necrosis factor in human inflammatory synovial fluids
83. Soluble tumor necrosis factor (TNF) receptors are upregulated in the sera and synovial fluids of patients with rheumatic diseases
84. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
85. The therapeutic effects of an engineered human anti-tumor necrosis factor antibody (CDP571) in rheumatoid arthritis
86. Clinical response of rheumatoid arthritis to anti- TNF(cA2) monoclonal antibody is related to administered dose and persistence of circulating antibody
87. Repeated therapy with moclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis
88. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor α monoclonal antibody: Combined with low-dose weekly methotrexate in rheumatoid arthritis
89. Infliximab (chimeric antitumor necrosis factor αmonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
90. The other side of TNF-targeted therapy of RA patients
91. The rational use of methotrexate in rheumatoid arthritis and other rheumatic disease
92. Methorexate update
93. The cellular pharmacology of methotrexate
94. The biological chemistry of folate receptors
95. Mechanisms of the effects of methotrexate
96. Phenotypic heterogeneity in cultured human head and neck squamous cell carcinoma lines with low-level methotrexate resistance
97. Cellular and molecular mechanisms of resistance to antifolate drugs: New analogues and approaches to overcome the resistance
98. The complete amino acid sequence of a human folate binding protein from KB cells determined from the cPNA
99. Identification of a novel folate receptor, a trancated receptor, and receptor type B in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity
100. Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis
101. Stable transfectants on human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolate
102. Folate receptor type beta is neutrophic lineage marker and is differentially expressed in myeloid leukemia
103. Expression of levels of functional folate receptor α and β are related to the number of N-glycosylated sites
104. Phase II study of the thymidylate synthetase inhibitor CB 3717 in colorectal cancer
105. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid